Corvus Pharmaceuticals
CRVS Small CapHealthcare · Biotechnology
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Corvus Pharmaceuticals en bref
Corvus Pharmaceuticals (CRVS) is currently trading at 11,52 € with a market capitalization of 969 M €. The 52-week range spans from 3,52 € to 23,42 €; the current price is 50.8% below the yearly high.
💰 Dividende
Corvus Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
7 analystes évaluent Corvus Pharmaceuticals (CRVS) au consensus : Achat Fort. L'objectif de cours moyen est de 28,80 €, soit un potentiel de +149.95% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 23,46 € à 36,50 €.
Corvus Pharmaceuticals : la thèse d'investissement en détail
Corvus Pharmaceuticals (CRVS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Strong Buy with an average price target implying roughly 149.95% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Short interest sits at 24.42% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
À surveiller
- The analyst consensus price target implies 149.95% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 0.35)
- –Positions vendeuses élevées (24.42%)
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (24.42%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Corvus Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
